B of A Securities Downgrades Rhythm Pharmaceuticals to Neutral, Lowers Price Target to $42
Portfolio Pulse from Benzinga Newsdesk
B of A Securities analyst Tazeen Ahmad downgraded Rhythm Pharmaceuticals (RYTM) from Buy to Neutral and reduced the price target from $49 to $42.

May 08, 2024 | 10:17 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Rhythm Pharmaceuticals was downgraded by B of A Securities from Buy to Neutral, with a price target reduction from $49 to $42.
The downgrade from Buy to Neutral by a major analyst and the reduction in price target are likely to negatively impact investor sentiment and could lead to a short-term decrease in RYTM's stock price. Analyst ratings and price targets are significant factors that investors consider when making investment decisions.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100